|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
5.53/3.76
|
企業價值
18.03B
|
資產負債 |
每股賬面淨值
14.24
|
現金流量 |
現金流量率
0.02
|
損益表 |
收益
1.70B
|
每股收益
22.21
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/09/21 01:40 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide. |